1. Headache is the _____ leading reason patients seek assistance within the emergency room.

2. What percentage of the general population in the United States has chronic migraine?

3. The REGAIN study showed a reduction in average monthly migraine days of 4.8 days for the 120 mg SC injection of which drug:

4. The only anti-CGRP mAb that is fully human and targets the CGRP receptor is ________.

5. Suggestive of a role in pain sensation, CGRP is localized primarily in __________.

6. In a cross-sectional study of approximately 1200 patients with chronic migraine, what percentage with MIDAS disability grade ≥2 traversed a series of 3 obstacles to successful chronic migraine care (consulted a physician, received a diagnosis, and been prescribed pharmacologic therapy)?

7. In a cross-sectional study of approximately 1200 patients with chronic migraine, what percentage of those who had consulted a physician received an accurate diagnosis?

8. Adherence to oral migraine-preventive medications among chronic migraineurs at 12 months is _____.

9. Which anti-CGRP mAb is administered through IV?

10. Which of the following is NOT a characteristic of mAbs that block CGRP activity?

11. The pain associated with migraine and its localization to the head and eye regions are heavily influenced by the_______.

12. Which anti-CGRP mAb is approved for monthly or quarterly dosing?

13. Small molecule CGRP receptor blocking compounds are a class known as _____.

14. Which of the following is NOT a risk factor for chronification of migraine?

15. Every day, pharmacists nationwide are asked to recommend an over-the-counter headache product an estimated _________.

« Return to Activity